News

Experimental Breast Cancer Drug Shows Promise in Aggressive Form of Disease

Results from studies in cell cultures and mouse models suggest that the experimental targeted therapy PU-H71 may be effective against one of the most aggressive forms of breast cancer.

Thursday, October 1, 2009
Dinshaw Patel (left) and David Allis
Linking Histones and Cancer

Structural biologists at Memorial Sloan Kettering Cancer Center are collaborating with biochemists and cell biologists at The Rockefeller University to study how cells read genetic instructions imprinted on histones, DNA’s packaging proteins.

Thursday, October 1, 2009
Researchers Find Genetic Key to Breast Cancer's Ability to Survive and Spread

New research led by investigators at Memorial Sloan Kettering Cancer Center sheds light on a genetic function that gives breast cancer cells the ability to survive and spread to the bone years after treatment has been administered.

Monday, July 6, 2009
Research Reveals What Drives Lung Cancer's Spread

A new study by researchers at Memorial Sloan Kettering Cancer Center reveals the genetic underpinnings of what causes lung cancer to quickly metastasize, or spread, to the brain and the bone - the two most prominent sites of lung cancer relapse.

Thursday, July 2, 2009
Memorial Sloan Kettering President Attends White House Signing

Memorial Sloan Kettering President Harold Varmus joined lawmakers, scientists, and patients on March 9 at a White House ceremony as President Barack Obama issued an executive order lifting the strict limits on human embryonic stem cell research.

Wednesday, July 1, 2009
Michael Overholtzer
An Interview with Michael Overholtzer

Michael Overholtzer is a recent recruit to Sloan Kettering Institute’s Cell Biology Program, he pairs this curiosity with a dedication to finding new ways to control disease.

Wednesday, July 1, 2009
Charles Sawyers (left) and Howard Scher
Advances in Development of New Targeted Therapy for Prostate Cancer Show Promise

A team of researchers led by Memorial Sloan Kettering physician-scientist Charles L. Sawyers has reported on the preclinical development and early results from the first clinical trial of a promising new drug for prostate cancer.

Wednesday, July 1, 2009
Dinshaw J. Patel
Dinshaw Patel Elected to the National Academy of Sciences

Dinshaw J. Patel, a Member in Sloan Kettering Institute’s Structural Biology Program and incumbent of the Abby Rockefeller Mauzé Chair in Experimental Therapeutics, was elected to the National Academy of Sciences at its 146th annual meeting in April.

Wednesday, July 1, 2009
Grégoire Altan-Bonnet
Two Young Investigators Named to New Bristol-Myers Squibb/James D. Robinson III Junior Faculty Chairs

Memorial Sloan Kettering’s Boards of Overseers and Managers have announced the creation of the Bristol-Myers Squibb/James D. Robinson III Junior Faculty Chairs and have named the first two incumbents: Sloan Kettering Institute’s Grégoire Altan-Bonnet and Songhai Shi.

Wednesday, July 1, 2009
Jennifer A. Zallen
Jennifer Zallen Selected as Early Career Scientist By Howard Hughes Medical Institute

Jennifer A. Zallen, a member of the Developmental Biology Program in the Sloan Kettering Institute, has been selected by the Howard Hughes Medical Institute (HHMI) as an Early Career Scientist.

Wednesday, July 1, 2009